| Trial ID: | L6396 |
| Source ID: | NCT05577728
|
| Associated Drug: |
New Use Of Semaglutide Injection
|
| Title: |
Prediction of the SEPRA Diabetes Trial in Healthcare Claims Data
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes Mellitus, Type 2
|
| Interventions: |
DRUG: New use of semaglutide injection|DRUG: New initiation of "standard of care" (SGL2i, 2nd generation SU, DPP-4i and GLP-1 RA except for semaglutide inj or oral)
|
| Outcome Measures: |
Primary: Long-term glycemic control defined as proportion of patients who will achieve an HbA1c of less than 7.0% (53.0 mmol/mol), Number of subjects, At year 1 | Secondary: Change in HbA1c, Change in HbA1c from baseline at 365 days after drug initiation., At 1 year|Number of hypoglycemic episodes leading to an inpatient admission or emergency room encounter., At 1 year
|
| Sponsor/Collaborators: |
Sponsor: Brigham and Women's Hospital
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
|
| Enrollment: |
2316
|
| Study Type: |
OBSERVATIONAL
|
| Study Designs: |
Observational Model: |Time Perspective: p
|
| Start Date: |
2021-07-01
|
| Completion Date: |
2022-10-31
|
| Results First Posted: |
|
| Last Update Posted: |
2024-09-25
|
| Locations: |
Brigham and Women's Hospital, Boston, Massachusetts, 02120, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT05577728
|
